|
|
(PRWEB) August 5, 2005 -- Infrared Sciences Corporation (“ISC”) has announced that it has completed a $2.1 million Series B Preferred Stock financing, acquiring the capital necessary to continue introducing Sentinel BreastScan to a broader market of doctors and patients. ISC completed a $1 million Series A Stock financing in October 2004.
Utilizing infrared imaging and proprietary software employing artificial intelligence techniques, Sentinel BreastScan is designed to be used as an adjunctive test with mammography, ultrasound or clinical examination for the early detection of breast cancer. It is an FDA-approved, non-invasive touchless procedure offered to women of any age, to help determine current breast health. The patient simply sits in a chair, facing the Sentinel BreastScan unit for a few minutes. Test results are immediately available in the form of a fully-interpreted, objective report, to assist in the doctor's determination of breast health.
“Sentinel BreastScan's ease of use and proprietary software are a quantum leap from any previous infrared imaging system,” explained ISC President Tom DiCicco. “It is the only system in the world that provides any doctor ready access to this early breast cancer detection data. Receiving this additional funding is a major step in enabling us to continue to bring the tremendous health benefits of Sentinel BreastScan to a broader base of doctors and their patients.”
ISC is now qualifying requests from doctors across America who are interested in having Sentinel BreastScan operational in their practices for no up-front fee or purchase costs. Doctors using the system determine the fee to be charged to patients for the procedure, and only pay ISC a small fee each time the system is used.
Unprecedented power for early detection
Sentinel BreastScan is unique among breast health evaluation tests in that it provides the doctor with physiological breast data, which can provide very early, indirect indications of areas of concern, as well as pinpointing the exact location of anomalies. This differs from the anatomical data provided by mammography, ultrasound or MRI, which require that any anomaly be sufficiently developed to be physically detectable.
Sentinel BreastScan is also a beneficial early detection method for young women of the age where detection is typically limited to palpation through self breast exams (SBE) or clinical breast exams (CBE), because cancers detected only through palpation are usually more advanced and therefore more threatening to the patient's health.
“Breast infrared imaging has the ability to detect the first signs that cancer may be forming up to 10 years before any other procedure can detect it,” said Mr. DiCicco, who also explained that the best indication of any abnormality is through a corroboration of different tests, including Sentinel BreastScan™. “As an adjunctive procedure, Sentinel BreastScan does not replace mammography or ultrasound,” he continued, “nor is it intended to stand alone as a single test that can determine overall breast health. Sentinel BreastScan can greatly improve the efficacy of those technologies by drawing attention to areas standard mammograms might miss – such as areas within dense breast tissue – or by localizing areas to be further investigated using ultrasound or MR technology.”
Several medical facilities have tested Sentinel BreastScan™ for more than four years as an adjunct for mammography and ultrasound. Two of the largest studies took place at Arena Oncology, in Great Neck, NY and Long Island Diagnostic Imaging, in Setauket, NY, and have accounted for testing of nearly 5,000 patients. Additional Clinical Trials are being organized in four of the leading medical universities in the United States, including one presently underway at the New York Presbyterian Hospital – Weill Medical College of Cornell University in New York City.
|
